Malaria positivity following a single oral dose of azithromycin among children in Burkina Faso: a randomized controlled trial.
Azithromycin
Malaria
Randomized controlled trial
Sahel
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
25 Mar 2022
25 Mar 2022
Historique:
received:
01
07
2021
accepted:
18
03
2022
entrez:
26
3
2022
pubmed:
27
3
2022
medline:
31
3
2022
Statut:
epublish
Résumé
Azithromycin is a broad-spectrum antibiotic that has moderate antimalarial activity and has been shown to reduce all-cause mortality when biannually administered to children under five in high mortality settings in sub-Saharan Africa. One potential mechanism for this observed reduction in mortality is via a reduction in malaria transmission. We evaluated whether a single oral dose of azithromycin reduces malaria positivity by rapid diagnostic test (RDT). We conducted an individually randomized placebo-controlled trial in Burkina Faso during the high malaria transmission season in August 2020. Children aged 8 days to 59 months old were randomized to a single oral dose of azithromycin (20 mg/kg) or matching placebo. At baseline and 14 days following treatment, we administered a rapid diagnostic test (RDT) to detect Plasmodium falciparum and measured tympanic temperature for all children. Caregiver-reported adverse events and clinic visits were recorded at the day 14 visit. We enrolled 449 children with 221 randomized to azithromycin and 228 to placebo. The median age was 32 months and 48% were female. A total of 8% of children had a positive RDT for malaria at baseline and 11% had a fever (tympanic temperature ≥ 37.5 °C). In the azithromycin arm, 8% of children had a positive RDT for malaria at 14 days compared to 7% in the placebo arm (P = 0.65). Fifteen percent of children in the azithromycin arm had a fever ≥ 37.5 °C compared to 21% in the placebo arm (P = 0.12). Caregivers of children in the azithromycin group had lower odds of reporting fever as an adverse event compared to children in the placebo group (OR 0.41, 95% CI 0.18-0.96, P = 0.04). Caregiver-reported clinic visits were uncommon, and there were no observed differences between arms (P = 0.32). We did not find evidence that a single oral dose of azithromycin reduced malaria positivity during the high transmission season. Caregiver-reported fever occurred less often in children receiving azithromycin compared to placebo, indicating that azithromycin may have some effect on non-malarial infections. Trial registration Clinicaltrials.gov NCT04315272, registered 19/03/2020.
Sections du résumé
BACKGROUND
BACKGROUND
Azithromycin is a broad-spectrum antibiotic that has moderate antimalarial activity and has been shown to reduce all-cause mortality when biannually administered to children under five in high mortality settings in sub-Saharan Africa. One potential mechanism for this observed reduction in mortality is via a reduction in malaria transmission.
METHODS
METHODS
We evaluated whether a single oral dose of azithromycin reduces malaria positivity by rapid diagnostic test (RDT). We conducted an individually randomized placebo-controlled trial in Burkina Faso during the high malaria transmission season in August 2020. Children aged 8 days to 59 months old were randomized to a single oral dose of azithromycin (20 mg/kg) or matching placebo. At baseline and 14 days following treatment, we administered a rapid diagnostic test (RDT) to detect Plasmodium falciparum and measured tympanic temperature for all children. Caregiver-reported adverse events and clinic visits were recorded at the day 14 visit.
RESULTS
RESULTS
We enrolled 449 children with 221 randomized to azithromycin and 228 to placebo. The median age was 32 months and 48% were female. A total of 8% of children had a positive RDT for malaria at baseline and 11% had a fever (tympanic temperature ≥ 37.5 °C). In the azithromycin arm, 8% of children had a positive RDT for malaria at 14 days compared to 7% in the placebo arm (P = 0.65). Fifteen percent of children in the azithromycin arm had a fever ≥ 37.5 °C compared to 21% in the placebo arm (P = 0.12). Caregivers of children in the azithromycin group had lower odds of reporting fever as an adverse event compared to children in the placebo group (OR 0.41, 95% CI 0.18-0.96, P = 0.04). Caregiver-reported clinic visits were uncommon, and there were no observed differences between arms (P = 0.32).
CONCLUSIONS
CONCLUSIONS
We did not find evidence that a single oral dose of azithromycin reduced malaria positivity during the high transmission season. Caregiver-reported fever occurred less often in children receiving azithromycin compared to placebo, indicating that azithromycin may have some effect on non-malarial infections. Trial registration Clinicaltrials.gov NCT04315272, registered 19/03/2020.
Identifiants
pubmed: 35337289
doi: 10.1186/s12879-022-07296-4
pii: 10.1186/s12879-022-07296-4
pmc: PMC8957146
doi:
Substances chimiques
Anti-Bacterial Agents
0
Antimalarials
0
Azithromycin
83905-01-5
Banques de données
ClinicalTrials.gov
['NCT04315272']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
285Subventions
Organisme : Bill and Melinda Gates Foundation
ID : OPP1187628
Informations de copyright
© 2022. The Author(s).
Références
Int J Epidemiol. 2006 Jun;35(3):691-704
pubmed: 16507643
N Engl J Med. 2018 Apr 26;378(17):1583-1592
pubmed: 29694816
Lancet. 2020 Dec 5;396(10265):1829-1840
pubmed: 33278936
Front Public Health. 2021 Sep 20;9:693281
pubmed: 34616704
Malar J. 2017 Feb 6;16(1):63
pubmed: 28166794
PLoS Med. 2019 Jun 25;16(6):e1002835
pubmed: 31237871
Glob Health Action. 2010 Sep 14;3:
pubmed: 20847837
PLoS Negl Trop Dis. 2018 Nov 12;12(11):e0006950
pubmed: 30419040
Malar J. 2014 Jan 27;13:30
pubmed: 24467946
Environ Monit Assess. 2019 Jun 28;191(Suppl 2):273
pubmed: 31254086
Drug Resist Updat. 2009 Feb-Apr;12(1-2):42-50
pubmed: 19285915
BMC Biol. 2020 Sep 29;18(1):133
pubmed: 32993629
Malar J. 2006 Jun 08;5:47
pubmed: 16762069
N Engl J Med. 2019 Jun 06;380(23):2197-2206
pubmed: 30699301
Am J Trop Med Hyg. 2019 May;100(5):1202-1203
pubmed: 30915959
BMJ Glob Health. 2019 Jul 29;4(4):e001582
pubmed: 31406591
Open Forum Infect Dis. 2016 Apr 13;3(2):ofw074
pubmed: 27419152
Malar J. 2019 Dec 3;18(1):389
pubmed: 31796025
JAMA. 2009 Sep 2;302(9):962-8
pubmed: 19724043
Malar J. 2015 Aug 05;14:300
pubmed: 26243295
Ann Pharmacother. 1998 Jul-Aug;32(7-8):785-93
pubmed: 9681095
Emerg Infect Dis. 2014 Jun;20(6):941-9
pubmed: 24865642
Am J Trop Med Hyg. 2020 Dec 21;104(3):1137-1141
pubmed: 33350370
Am J Trop Med Hyg. 2011 Aug;85(2):291-4
pubmed: 21813850
Trans R Soc Trop Med Hyg. 2005 Jan;99(1):6-12
pubmed: 15550255
Am J Trop Med Hyg. 2017 Sep;97(3):696-701
pubmed: 28722569
Clin Infect Dis. 2021 Oct 5;73(7):e2379-e2386
pubmed: 33417683
Am J Trop Med Hyg. 2020 Sep;103(3):1329-1334
pubmed: 32342841
Malar J. 2019 Aug 23;18(1):284
pubmed: 31443654
Am J Trop Med Hyg. 2014 May;90(5):846-51
pubmed: 24615132